ASX:ANR

Anatara Lifesciences (ANR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,950 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

ANR Stock News Headlines

Edwards Lifesciences
Eris Lifesciences Ltd.
Dems have chosen Biden replacement?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Mega Lifesciences PCL
Zydus Lifesciences Ltd.
Innovation begins with collaboration: Steven Lydeamore
Anatara Lifesciences Ltd (ANR.AX)
Dems have chosen Biden replacement?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd (ANR)
Anatara Lifesciences Limited (ANR.AX) Investor Presentation
See More Headlines
Receive ANR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anatara Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.25 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.65
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. David Lionel Brookes F.A.C.I.D. (Age 64)
    FACRRM, FAICD, MBBS, Executive Chairman
    Comp: $168.21k
  • Mr. John Michailidis B.Sc.
    EMBA, M.A.I.C.D., COO & Executive Director
  • Mr. Simon Erskine
    Chief Development Officer
  • Jane Lowe
    Managing Director of IR Department
  • Dr. Stephen Denaro AGIA
    BCom, CA, GradDipApp CG, MAICD, Company Secretary
  • Ms. Hayley van der Meer B Biomed Sc
    Grad Dip Marketing Management, Commercial Manager

ANR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Anatara Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anatara Lifesciences investors own include Woodside Petroleum (WPL), Temple & Webster Group (TPW), Brompton Oil Split (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP).

This page (ASX:ANR) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners